With the end of year quickly approaching, the Aesthetics team at Guidepoint Qsight reviewed several years of trending data from Qsight Aesthetics Point-of-Sale and Qsight Aesthetics Tracker to unpack how behavior changes at MedSpas and Aesthetics practices in and around the holiday season.

As 2023 began with lingering economic concerns from 2022 (inflation, rising interest rates, risk of recession, etc.), the aesthetics industry’s hope for continued strong growth may be challenged.

As MedSpas become an important growth driver for the medical aesthetics industry in the U.S., Qsight’s aesthetics point-of-sale data...

Guidepoint Qsight’s proprietary Aesthetics data examines patient spending in the United States, providing insight into brand retention in the Neurotoxin space. Using a sample of patients who had at least three Neurotoxin injection visits over at least six months (n=159,657), we reviewed what brand they started on (first visit) and which brand they used in…

Guidepoint Qsight’s data captured a surge in spending on non-surgical medical aesthetics treatments in March and April 2021. Neurotoxins, dermal fillers, and non-surgical skin tightening reached unprecedented levels in March 2021 with a continued strong growth trend into April, according to Qsight’s aesthetics point-of-sale data. Younger patients are contributing more to the 2021 aesthetic sales…

Guidepoint Qsight is excited to announce the launch of a new Medical Aesthetics market intelligence offering where you can track the latest trends in the U.S. Medical Aesthetics space with insight into several categories, including Neurotoxins, Dermal Fillers, Non-Surgical Fat Reduction, Skin Tightening, Hormone Replacement Therapy, and several more. We’ve used our Medical Aesthetics dataset…

With COVID-19 continuing to create uncertainty, Guidepoint Qsight has gathered insights from U.S. physicians across healthcare markets on their expected change in procedure volumes at their facility in 2021. Collectively, over half of all physicians believe they will see higher procedure volumes in 2021 than they did in 2020. The Aesthetics market has the highest…

Following temporary bans on elective procedures earlier this year due to the COVID-19 pandemic, Guidepoint Qsight was able to capture the effects on aesthetics volumes. Following the sharp declines in March-May, Breast Implant procedures resumed with a tremendous amount of backlog and rebounded back to pre-COVID-19 levels in June 2020 and even accelerating to a…